Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Evaluation of Accelerator Mass Spectrometry in a Human Mass Balance and Pharmacokinetic Study–Experience with14C-labeled (R)-6-[Amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1- methyl-2(1H)-quinolinone (R115777), a Farnesyl Transferase Inhibitor

R. C. Garner, I. Goris, A. A. E. Laenen, E. Vanhoutte, W. Meuldermans, S. Gregory, J. V. Garner, D. Leong, M. Whattam, A. Calam and C. A. W. Snel
Drug Metabolism and Disposition July 2002, 30 (7) 823-830; DOI: https://doi.org/10.1124/dmd.30.7.823
R. C. Garner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I. Goris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. A. E. Laenen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Vanhoutte
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. Meuldermans
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Gregory
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. V. Garner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Leong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Whattam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Calam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. A. W. Snel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Accelerator mass spectrometry (AMS) has been used in a human mass balance and metabolism study to analyze samples taken from four healthy male adult subjects administered nanoCurie doses of the farnesyl transferase inhibitor 14C-labeled (R)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone ([14C]R115777). Plasma, urine, and feces samples were collected at fixed timepoints after oral administration of 50 mg [14C]R115777 (25.4 Bq/mg or 687 pCi/mg i.e., equivalent to 76.257 × 103 dpm) per subject. AMS analysis showed that drug-related 14C was present in the plasma samples with Cmax values ranging from 1.6055 to 2.9074 dpm/ml (1.0525–1.9047 μg/ml) attmax = 2 to 3 h. TheCmax values for acetonitrile extracts of plasma samples ranged from 0.3724 to 0.7490 dpm/ml in the four male subjects. Drug-related 14C was eliminated from the body both in the urine and the feces, with a mean total recovery of 79.8 ± 12.9% in the feces and 13.7 ± 6.2% in the urine. The majority of drug-related radioactivity in urine and feces was excreted within the first 48 h. High-performance liquid chromatography (HPLC)-AMS profiles were generated from radioactive parent drug plus metabolites from pooled diluted urine, plasma, and methanolic feces extracts and matched to retention times of synthetic reference substances, postulated as metabolites. All HPLC separations used no more than 5 dpm injected on-column. The radioactive metabolite profiles obtained compared well with those obtained using liquid chromatography/tandem mass spectometry. This study demonstrates the use of AMS in a human phase I study in which the administered radioactive dose was at least 1000-fold lower than that used for conventional radioactive studies.

Footnotes

  • This research was financially supported by Janssen Pharmaceutica, Beerse, Belgium.

  • Abbreviations used are::
    AMS
    accelerator mass spectrometry
    HPLC
    high-performance liquid chromatography
    DMSO
    dimethyl sulfoxide
    LC/MS/MS
    liquid chromatography/tandem mass spectometry
    R115777
    (R)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone
    • Received January 22, 2002.
    • Accepted March 29, 2002.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 30 (7)
Drug Metabolism and Disposition
Vol. 30, Issue 7
1 Jul 2002
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of Accelerator Mass Spectrometry in a Human Mass Balance and Pharmacokinetic Study–Experience with14C-labeled (R)-6-[Amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1- methyl-2(1H)-quinolinone (R115777), a Farnesyl …
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Evaluation of Accelerator Mass Spectrometry in a Human Mass Balance and Pharmacokinetic Study–Experience with14C-labeled (R)-6-[Amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1- methyl-2(1H)-quinolinone (R115777), a Farnesyl Transferase Inhibitor

R. C. Garner, I. Goris, A. A. E. Laenen, E. Vanhoutte, W. Meuldermans, S. Gregory, J. V. Garner, D. Leong, M. Whattam, A. Calam and C. A. W. Snel
Drug Metabolism and Disposition July 1, 2002, 30 (7) 823-830; DOI: https://doi.org/10.1124/dmd.30.7.823

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Evaluation of Accelerator Mass Spectrometry in a Human Mass Balance and Pharmacokinetic Study–Experience with14C-labeled (R)-6-[Amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1- methyl-2(1H)-quinolinone (R115777), a Farnesyl Transferase Inhibitor

R. C. Garner, I. Goris, A. A. E. Laenen, E. Vanhoutte, W. Meuldermans, S. Gregory, J. V. Garner, D. Leong, M. Whattam, A. Calam and C. A. W. Snel
Drug Metabolism and Disposition July 1, 2002, 30 (7) 823-830; DOI: https://doi.org/10.1124/dmd.30.7.823
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Identification of payload-containing catabolites of ADCs
  • PK Interactions of Licorice with Cytochrome P450s
  • Biotransformation of Trastuzumab and Pertuzumab
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics